Administrative Core

项目摘要/摘要： 新冠肺炎体现了对下一场健康危机措手不及的可怕后果。一场迫在眉睫的危机 涉及抗生素耐药性细菌感染的潜伏上升，需要我们在我们的 U19名为《抗击抗药性感染的创新策略》的申请 RFA-AI-20-001(抗击耐药细菌跨学科研究单位(CARBIRU))。 我们的提议被用来将基础科学转化为新类型的节省抗生素的普通药物 美国的感染以及常见的医院获得性感染。这个U19应用程序利用 多部门、多机构和跨学科的高度积极的微生物学、细胞 生物/生理学、免疫学和药物化学研究人员将开发节省抗生素的药物 能够：一)治疗常见感染；和/或二)增加敏感性的治疗药物和化合物 到目前可用的抗生素武器库。行政核心(AC)将负责协调 三个研究项目和两个科学核心的活动和监测进展情况 U19项目的总体目标。为了实现这一目标，AC Leader在一名高管的帮助下 由研究项目和核心领导组成的委员会将监督和协调 项目成员和核心成员的活动：一)促进频繁互动；二)支持 交流数据、方法和想法；三)促进与机构和外部专家的互动，以 为更好地发挥整个计划的作用和将计划的调查结果转化为 治疗发展；以及iv)向授权机构协调财务和科学进展报告 工作人员。此外，咨询委员会将协调积极参与U19，以确保其全面成功。

PROJECT SUMMARY/ ABSTRACT: COVID-19 exemplifies the dire consequences of being unprepared for the next health crisis. One looming crisis involves the insidious rise of antibiotic resistant bacterial infections, necessitating the research described in our U19 application entitled “Innovative strategies to combat antibiotic-resistant infections” in response to RFA-AI-20-001 (Combating Antibiotic-resistant Bacteria Interdisciplinary Research Units (CARBIRU)). Our proposal is leveraged to translate basic science into new types of antibiotic-sparing medicines for common infections in the United States as well as common hospital-acquired infections. This U19 application utilizes a multi-departmental, multi-institutional, and interdisciplinary group of highly motivated microbiology, cell biology/physiology, immunology and medicinal chemistry researchers to develop antibiotic-sparing therapeutics and compounds that are capable of: i) treating common infections; and/or ii) increasing sensitivity to the current arsenal of available antibiotics. The Administrative Core (AC) will be responsible for coordinating the activities and monitoring the progress of the three research projects and the two scientific cores to achieve the overall goals of the U19 program. To accomplish this, the AC Leader, with the help of an Executive Committee comprising of the Leaders of the Research Projects and Cores, will oversee and coordinate the activities of the members of the Projects and Cores by: i) fostering frequent interactions; ii) supporting the exchange of data, methodologies, and ideas; iii) facilitating interactions with institutional and outside experts to gain advice for better functioning of the overall program and for translation of the program's findings into therapeutics development; and iv) coordinating financial and scientific progress reporting to granting agency staff. In addition, the AC will coordinate active participation in the U19 to ensure its overall success.